WA
AKRO

WPG Advisers’s Akero Therapeutics AKRO Stock Holding History

WPG Advisers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14
Closed -$389 – 1433
2024
Q4 		$389 Buy
+14
New +$424 ﹤0.01% 1383

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WPG Advisers's AKRO Position: Q1 2025 in Review

WPG Advisers sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 14 shares — an estimated $389 sold.

WPG Advisers first reported a position in AKRO in Q4 2024 and held it in 1 quarter. The position peaked at $389 in Q4 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • WPG Advisers reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • WPG Advisers sold 14 Akero Therapeutics shares in Q1 2025, an estimated $389.
  • WPG Advisers first reported a position in Akero Therapeutics in Q4 2024 and held it in 1 quarter.
  • WPG Advisers's Akero Therapeutics position peaked at $389 in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on WPG Advisers's 13F filing for Q1 2025, filed 15 May 2025.